Nanobiotix gets FDA fast track status for NBTXR3 to investigate in head and neck cancer

Nanobiotix gets FDA fast track status for NBTXR3 to investigate in head and neck cancer

Submitted by admin on February 11, 2020 - 10:29am
Source: 
Pharmaceutical Business Review
News Tags: 
Nanobiotix
FDA
NBTXR3
cetuximab
squamous cell carcinoma of the head and neck
Headline: 
Nanobiotix gets FDA fast track status for NBTXR3 to investigate in head and neck cancer
snippet: 

The designation has been granted for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, to treat patients with locally advanced head and neck squamous cell cancer (HNSCC) who are not eligible for platinum-based chemotherapy.

Do Not Allow Advertisers to Use My Personal information